683 Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

683 Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.4M	Sell	355,000 -25,669	-7%	-$2.27M	1.95%	10
2025 Q4	$33.2M	Sell	380,669 -26,831	-7%	-$2.2M	1.45%	14
2025 Q3	$27.1M	Sell	407,500 -37,500	-8%	-$2.13M	1.41%	19
2025 Q2	$24.6M	Sell	445,000 -55,000	-11%	-$2.64M	1.62%	16
2025 Q1	$24.2M	Buy	500,000 +90,000	+22%	+$3.77M	1.67%	16
2024 Q4	$15.8M	Sell	410,000 -10,000	-2%	-$436K	0.98%	23
2024 Q3	$18.9M	Sell	420,000 -184,449	-31%	-$7.45M	1.44%	21
2024 Q2	$20.9M	Sell	604,449 -95,551	-14%	-$2.8M	1.58%	17
2024 Q1	$20.3M	Sell	700,000 -15,000	-2%	-$408K	1.48%	19
2023 Q4	$16.4M	Sell	715,000 -17,784	-2%	-$311K	1.34%	24
2023 Q3	$12.2M	Sell	732,784 -81,216	-10%	-$1.58M	0.95%	33
2023 Q2	$22.5M	Buy	814,000 +23,000	+3%	+$576K	1.61%	18
2023 Q1	$18.2M	Buy	791,000 +583,200	+281%	+$9.79M	1.36%	22
2022 Q4	$2.27M	Buy	+207,800	New	+$1.75M	0.19%	96

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

683 Capital Management's PTGX Position: Q1 2026 in Review

683 Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 6.7% in Q1 2026, selling an estimated $2.27M and leaving 355,000 shares worth $37.4M. The position accounts for 1.95% of the portfolio, ranked #10.

683 Capital Management first reported a position in PTGX in Q4 2022 and has held it in 14 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

683 Capital Management held 355,000 shares of Protagonist Therapeutics worth $37.4M as of Q1 2026.
683 Capital Management sold 25,669 Protagonist Therapeutics shares in Q1 2026, an estimated $2.27M.
Protagonist Therapeutics made up 1.95% of 683 Capital Management's portfolio in Q1 2026, its #10 holding.
683 Capital Management first reported a position in Protagonist Therapeutics in Q4 2022 and has held it in 14 quarters since.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.